Literature DB >> 18937974

Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis.

Ayalew Tefferi1, Shireen Sirhan, Yi Sun, Terra Lasho, Christy M Finke, James Weisberger, Sherri Bale, John Compton, Charles A LeDuc, Animesh Pardanani, Erik C Thorland, Yuriy Shevchenko, Marc Grodman, Wendy K Chung.   

Abstract

Comparative genomic hybridization (CGH), using oligo arrays with either 44,000 or 105,000 oligonucleotides, was performed on granulocyte-derived DNA from 71 patients with BCR-ABL-negative classic myeloproliferative neoplasms (MPNs): 32 primary myelofibrosis (PMF), 26 polycythemia vera (PV) and 13 essential thrombocythemia (ET). Copy number changes (CNCs) were detected in 44%, 35%, and 15% of the cases with PMF, PV and ET, respectively. In ET and PMF, CNCs were more frequently detected in the presence of JAK2V617F (50% vs. 19%; p=0.05). Conventional chromosome analysis was obtained in 57 patients either at diagnosis or within 1 year of the array CGH study; all 21 patients with PV and 11 with ET displayed normal cytogenetic findings despite the presence of CNCs in 29% and 18%, respectively. In PMF, the respective rates of CNCs and abnormal karyotype were 48% and 36%; karyotypic abnormalities, including unbalanced translocations, were often detected by array CGH as chromosomal gains or losses. This preliminary report suggests a potential value for array CGH in terms of both clinical diagnostics and genomic research in MPNs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18937974     DOI: 10.1016/j.leukres.2008.09.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

1.  Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms.

Authors:  K L Rice; X Lin; K Wolniak; B L Ebert; W Berkofsky-Fessler; M Buzzai; Y Sun; C Xi; P Elkin; R Levine; T Golub; D G Gilliland; J D Crispino; J D Licht; W Zhang
Journal:  Blood Cancer J       Date:  2011-11-11       Impact factor: 11.037

2.  Genetic Alterations in Essential Thrombocythemia Progression to Acute Myeloid Leukemia: A Case Series and Review of the Literature.

Authors:  Jackline P Ayres-Silva; Martin H Bonamino; Maria E Gouveia; Barbara C R Monte-Mor; Diego F Coutinho; Adelmo H Daumas; Cristiana Solza; Esteban Braggio; Ilana Renault Zalcberg
Journal:  Front Oncol       Date:  2018-02-19       Impact factor: 6.244

3.  A Novel Acquired t(2;4)(q36.1;q24) with a Concurrent Submicroscopic del(4)(q23q24) in An Adult with Polycythemia Vera.

Authors:  Eigil Kjeldsen
Journal:  Cancers (Basel)       Date:  2018-06-25       Impact factor: 6.639

4.  Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.

Authors:  Mónica Mejía-Ochoa; Paola Andrea Acevedo Toro; Jaiberth Antonio Cardona-Arias
Journal:  BMC Cancer       Date:  2019-06-17       Impact factor: 4.430

5.  Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.

Authors:  Leonardo Caires Dos Santos; Juliana Corrêa da Costa Ribeiro; Neusa Pereira Silva; Janete Cerutti; Maria Regina Regis da Silva; Maria de Lourdes Lopes Ferrari Chauffaille
Journal:  Rev Bras Hematol Hemoter       Date:  2011
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.